Pharmacotherapeutic management of locally advanced prostate cancer: current status.

Détails

ID Serval
serval:BIB_D44530F21289
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Pharmacotherapeutic management of locally advanced prostate cancer: current status.
Périodique
Drugs
Auteur(s)
Martin J.M., Supiot S., Berthold D.R.
ISSN
1179-1950 (Electronic)
ISSN-L
0012-6667
Statut éditorial
Publié
Date de publication
28/05/2011
Peer-reviewed
Oui
Volume
71
Numéro
8
Pages
1019-1041
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review

Résumé
Locally advanced prostate cancer (LAPC) is a heterogeneous entity usually embracing T3-4 and/or pelvic lymph-node-positive disease in the absence of established metastases. Outcomes for LAPC with single therapies have traditionally been poor, leading to the investigation of adjuvant therapies. Prostate cancer is a hormonally sensitive tumour, which usually responds to pharmacological manipulation of the androgen receptor or its testosterone-related ligands. As such, androgen deprivation therapy (ADT) has become an important adjuvant strategy for the treatment of LAPC, particularly for patients managed primarily with radiotherapy. Such results have generally not been replicated in surgical patients. With increased use of ADT has come improved awareness of the numerous toxicities associated with long-term use of these agents, as well as the development of strategies for minimizing ADT exposure and actively managing adverse effects. Several trials are exploring agents to enhance radiation cell sensitivity as well as the application of adjuvant docetaxel, an agent with proven efficacy in the metastatic, castrate-resistant setting. The recent work showing activity of cabazitaxel, sipuleucel-T and abiraterone for castrate-resistant disease in the post-docetaxel setting will see these agents investigated in conjunction with definitive surgery and radiotherapy.

Mots-clé
Androgen Antagonists/adverse effects, Androgen Antagonists/therapeutic use, Antineoplastic Agents, Hormonal/adverse effects, Antineoplastic Agents, Hormonal/therapeutic use, Humans, Male, Prostatic Neoplasms/diagnosis, Prostatic Neoplasms/drug therapy, Prostatic Neoplasms/radiotherapy, Prostatic Neoplasms/surgery, Randomized Controlled Trials as Topic
Pubmed
Création de la notice
05/10/2011 10:02
Dernière modification de la notice
20/08/2019 16:54
Données d'usage